IRADIMED CORP (IRMD) Stock Fundamental Analysis
USA - NASDAQ:IRMD - US46266A1097 - Common Stock
84.35 USD
-0.15 (-0.18%)
84.35 USD
0 (0%)
Taking everything into account, IRMD scores 7 out of 10 in our fundamental rating. IRMD was compared to 189 industry peers in the Health Care Equipment & Supplies industry. IRMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IRMD has a correct valuation and a medium growth rate. With these ratings, IRMD could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
IRMD had positive earnings in the past year.
In the past year IRMD had a positive cash flow from operations.
In the past 5 years IRMD has always been profitable.
Each year in the past 5 years IRMD had a positive operating cash flow.
1.2 Ratios
IRMD's Return On Assets of 18.47% is amongst the best of the industry. IRMD outperforms 97.88% of its industry peers.
IRMD has a better Return On Equity (21.54%) than 93.65% of its industry peers.
IRMD has a Return On Invested Capital of 19.30%. This is amongst the best in the industry. IRMD outperforms 97.35% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IRMD is significantly above the industry average of 8.99%.
The 3 year average ROIC (18.78%) for IRMD is below the current ROIC(19.30%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.47% | ||
| ROE | 21.54% | ||
| ROIC | 19.3% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of IRMD (26.31%) is better than 94.18% of its industry peers.
IRMD's Profit Margin has been stable in the last couple of years.
With an excellent Operating Margin value of 30.87%, IRMD belongs to the best of the industry, outperforming 97.88% of the companies in the same industry.
IRMD's Operating Margin has improved in the last couple of years.
IRMD has a better Gross Margin (77.07%) than 89.42% of its industry peers.
In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.87% | ||
| PM (TTM) | 26.31% | ||
| GM | 77.07% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IRMD is creating value.
The number of shares outstanding for IRMD has been increased compared to 1 year ago.
IRMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 42.38 indicates that IRMD is not in any danger for bankruptcy at the moment.
The Altman-Z score of IRMD (42.38) is better than 99.47% of its industry peers.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 42.38 |
ROIC/WACC2.21
WACC8.75%
2.3 Liquidity
A Current Ratio of 6.64 indicates that IRMD has no problem at all paying its short term obligations.
IRMD has a better Current ratio (6.64) than 84.13% of its industry peers.
IRMD has a Quick Ratio of 5.72. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.72, IRMD belongs to the top of the industry, outperforming 85.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.64 | ||
| Quick Ratio | 5.72 |
3. Growth
3.1 Past
IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.75%, which is quite good.
IRMD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.92% yearly.
Looking at the last year, IRMD shows a quite strong growth in Revenue. The Revenue has grown by 12.91% in the last year.
The Revenue has been growing by 13.71% on average over the past years. This is quite good.
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%
3.2 Future
The Earnings Per Share is expected to grow by 9.26% on average over the next years. This is quite good.
Based on estimates for the next years, IRMD will show a quite strong growth in Revenue. The Revenue will grow by 8.97% on average per year.
EPS Next Y12.51%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue Next Year11.05%
Revenue Next 2Y11.16%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 46.35, the valuation of IRMD can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 68.25% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 25.89. IRMD is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 39.47, IRMD can be considered very expensive at the moment.
71.43% of the companies in the same industry are more expensive than IRMD, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.59, IRMD is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.35 | ||
| Fwd PE | 39.47 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than the industry average as 68.25% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, IRMD is valued a bit cheaper than the industry average as 70.90% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 76.91 | ||
| EV/EBITDA | 39.42 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IRMD does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IRMD may justify a higher PE ratio.
PEG (NY)3.7
PEG (5Y)3.33
EPS Next 2Y13.8%
EPS Next 3Y9.26%
5. Dividend
5.1 Amount
With a yearly dividend of 0.80%, IRMD is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 1.89, IRMD pays a better dividend. On top of this IRMD pays more dividend than 91.53% of the companies listed in the same industry.
With a Dividend Yield of 0.80, IRMD pays less dividend than the S&P500 average, which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.8% |
5.2 History
IRMD has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
IRMD pays out 39.59% of its income as dividend. This is a sustainable payout ratio.
DP39.59%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
84.35
-0.15 (-0.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners59.43%
Inst Owner Change-3.8%
Ins Owners36.81%
Ins Owner Change1.03%
Market Cap1.07B
Revenue(TTM)80.51M
Net Income(TTM)21.18M
Analysts82.5
Price Target76.5 (-9.31%)
Short Float %1.99%
Short Ratio3.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.8% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.59%
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.85%
Min EPS beat(2)1.27%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)2.54%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)4.28%
EPS beat(12)10
Avg EPS beat(12)6.04%
EPS beat(16)14
Avg EPS beat(16)9.77%
Revenue beat(2)2
Avg Revenue beat(2)0.71%
Min Revenue beat(2)0.01%
Max Revenue beat(2)1.41%
Revenue beat(4)2
Avg Revenue beat(4)-0.08%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)1.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.25%
Revenue beat(12)6
Avg Revenue beat(12)-0.02%
Revenue beat(16)7
Avg Revenue beat(16)-0.16%
PT rev (1m)2.04%
PT rev (3m)2.04%
EPS NQ rev (1m)-1.09%
EPS NQ rev (3m)-1.09%
EPS NY rev (1m)-1.62%
EPS NY rev (3m)4.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)2.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.35 | ||
| Fwd PE | 39.47 | ||
| P/S | 13.33 | ||
| P/FCF | 76.91 | ||
| P/OCF | 42.9 | ||
| P/B | 10.91 | ||
| P/tB | 11.3 | ||
| EV/EBITDA | 39.42 |
EPS(TTM)1.82
EY2.16%
EPS(NY)2.14
Fwd EY2.53%
FCF(TTM)1.1
FCFY1.3%
OCF(TTM)1.97
OCFY2.33%
SpS6.33
BVpS7.73
TBVpS7.47
PEG (NY)3.7
PEG (5Y)3.33
Graham Number17.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.47% | ||
| ROE | 21.54% | ||
| ROCE | 24.38% | ||
| ROIC | 19.3% | ||
| ROICexc | 43.34% | ||
| ROICexgc | 46.82% | ||
| OM | 30.87% | ||
| PM (TTM) | 26.31% | ||
| GM | 77.07% | ||
| FCFM | 17.33% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexgc growth 3Y-6.9%
ROICexgc growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score4
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1128.47% | ||
| Cap/Sales | 13.74% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 96.82% | ||
| Profit Quality | 65.85% | ||
| Current Ratio | 6.64 | ||
| Quick Ratio | 5.72 | ||
| Altman-Z | 42.38 |
F-Score4
WACC8.75%
ROIC/WACC2.21
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)13.75%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%9.3%
EPS Next Y12.51%
EPS Next 2Y13.8%
EPS Next 3Y9.26%
EPS Next 5YN/A
Revenue 1Y (TTM)12.91%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%15.69%
Revenue Next Year11.05%
Revenue Next 2Y11.16%
Revenue Next 3Y8.97%
Revenue Next 5YN/A
EBIT growth 1Y16.55%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y194.31%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y98.66%
OCF growth 3Y31.53%
OCF growth 5Y20.16%
IRADIMED CORP / IRMD FAQ
Can you provide the ChartMill fundamental rating for IRADIMED CORP?
ChartMill assigns a fundamental rating of 7 / 10 to IRMD.
What is the valuation status of IRADIMED CORP (IRMD) stock?
ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.
Can you provide the profitability details for IRADIMED CORP?
IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.
How financially healthy is IRADIMED CORP?
The financial health rating of IRADIMED CORP (IRMD) is 9 / 10.
Is the dividend of IRADIMED CORP sustainable?
The dividend rating of IRADIMED CORP (IRMD) is 3 / 10 and the dividend payout ratio is 39.59%.